Key result
Potential drug interactions involving QT-prolonging medications occurred in 4.6% of patients prescribed a QT-prolonging drug, with 90.1% of these occurring in patients with other risk factors.
Why the study?
What is the frequency of potential drug interactions involving QT-prolonging medications in a health plan population?
Population
228,550 health plan members with at least one prescription for a QT-prolonging drug, drawn from a sample of…
Design
Cohort
Follow-up
January 1999 to July 2001
Authors
Loading...
Supports heightened awareness of QT interactions mainly in high-risk patients; hypothesis-generating for outcome-focused studies.
Observational (n=228,550)
Yes
What is the frequency of potential drug interactions involving QT-prolonging medications in a health plan population?
High-risk concurrent use of QT-prolonging medications occurs in nearly 5% of patients prescribed these drugs, highlighting a significant area for targeted safety interventions.
LaPointe et al. (2005) conducted an observational in Prescription for a QT-prolonging drug (n=228,550). Potential drug interactions involving QT-prolonging medications was evaluated on Frequency of potential drug interactions involving QT-prolonging medications. Potential drug interactions involving QT-prolonging medications occurred in 4.6% of patients prescribed a QT-prolonging drug, with 90.1% of these occurring in patients with other risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: